SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Relugolix (Primary)
- Indications Endometriosis; Pain
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT 2
- Sponsors Myovant Sciences
- 07 Aug 2018 According to a Myovant Sciences media release, safety and efficacy data expected in 2019.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2017 New trial record